Interestingly, the as-yet unnamed conversational agent is currently an open-source project, meaning that anyone can contribute to the development of the bot’s codebase. The project is still in its earlier stages, but has great potential to help scientists, researchers, and care teams better understand how Alzheimer’s disease affects the brain. A Russian version of the bot is already available, and an English version is expected at some point this year.
This chatbot aims to make medical diagnoses faster, easier, and more transparent for both patients and physicians – think of it like an intelligent version of WebMD that you can talk to. MedWhat is powered by a sophisticated machine learning system that offers increasingly accurate responses to user questions based on behaviors that it “learns” by interacting with human beings.
“There is hope that consumers will be keen on experimenting with bots to make things happen for them. It used to be like that in the mobile app world 4+ years ago. When somebody told you back then… ‘I have built an app for X’… You most likely would give it a try. Now, nobody does this. It is probably too late to build an app company as an indie developer. But with bots… consumers’ attention spans are hopefully going to be wide open/receptive again!” — Niko Bonatsos, Managing Director at General Catalyst